KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Assets: 2013-2024

Historic Other Non-Current Assets for Xenon Pharmaceuticals (XENE) over the last 7 years, with Dec 2024 value amounting to $7.5 million.

  • Xenon Pharmaceuticals' Other Non-Current Assets fell 4.78% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 4.78%. This contributed to the annual value of $7.5 million for FY2024, which is 1.35% up from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Other Non-Current Assets of $7.5 million as of FY2024, which was up 1.35% from $7.4 million recorded in FY2023.
  • Xenon Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $7.8 million during FY2022, with a 5-year trough of $7.4 million in FY2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $7.5 million (2024), whereas its average is $7.5 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first decreased by 4.58% in 2023, then increased by 1.35% in 2024.
  • Xenon Pharmaceuticals' Other Non-Current Assets (Yearly) stood at $7.8 million in 2022, then decreased by 4.58% to $7.4 million in 2023, then grew by 1.35% to $7.5 million in 2024.